Tiny study aims to unlock how blood filtering helps CIDP
NCT ID NCT04742374
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at two types of plasmapheresis (blood filtering) in 8 people with CIDP, a rare nerve disorder causing weakness. The goal was to see how each method affects immune cells in the blood. It is a very early, small study focused on understanding how these treatments work, not on finding a cure.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- plasmapheresis (blood filtering)
- What this could lead to
- If successful, this could help doctors understand why plasmapheresis works for CIDP and choose the best technique.
- What could go wrong
- This is a very small, early-phase study with only 8 people. It is designed to gather information, not to prove a treatment works. Results may not apply to all CIDP patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
8 people
The number who actually took part.
- Started
-
Mar 2021
- Finished
-
Dec 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with confirmed Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) without pathogenic antibodies and stable under therapeutic plasmapheresis with one session every 2-3 weeks for at least two months. * Patients who have given free written informed consent. * Patients who have signed the consent form. * Patients affiliated to or beneficiaries of a health insurance scheme. * Adult patients (≥18 ans). * Healthy subjects of the same age and sex Exclusion Criteria: * Patients Under the age of 18. * Patients under immunosuppressive treatment for less than 3 months. * Patients participating in Category 1 research involving human subjects. * Patients in an exclusion period determined by another study. * Patients under legal protection, guardianship or curatorship. * Patients unable to express consent. * Patients for whom it is impossible to give informed information. * Pregnant, parturient or breastfeeding patients. * Healthy subject with chronic pathology or drug treatment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Polyradiculoneuropathy, chronic inflammatory demyelinating are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Olivier MORANNE
Nîmes, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.